Dolutegravir is a preferred antiretroviral drug for human immunodeficiency virus (HIV)-infected patients following solid organ transplantation. It has potent antiretroviral activity and does not interact with calcineurin inhibitors. We describe a case of an HIV-infected kidney transplant patient, who was noted to have a rising serum creatinine following initiation of dolutegravir. At first, an acute rejection episode was suspected, but this finding was later attributed to inhibition of creatinine secretion by dolutegravir. We suggest that an awareness of this potential effect of dolutegravir is important for providers who take care of HIV-positive kidney transplant recipients, in order to prevent potentially unnecessary testing.
Serum creatinine elevation after switch to dolutegravir in a human immunodeficiency virus-positive kidney transplant recipient
Creators
D. H. Lee - Drexel University
G. E. Malat - Drexel University
T. E. Bias - Drexel University
M. N. Harhay - Drexel University
K. Ranganna - Drexel University
A. M. Doyle - Drexel University
Publication Details
Transplant infectious disease, v 18(4), pp 625-627
Publisher
Wiley
Number of pages
3
Grant note
K23DK105207 / National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
K23DK105207 / NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
Resource Type
Journal article
Language
English
Academic Unit
Radiation Oncology (and Nuclear Medicine); Medicine (Graduate); College of Medicine; Design; Surgery
Web of Science ID
WOS:000385704700019
Scopus ID
2-s2.0-84981156865
Other Identifier
991019169419704721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool: